Virtual Discovery

Virtual Discovery is a private, services-focused computational drug discovery company spun out from a Harvard Medical School lab. Its core offering is providing access to ultra-large virtual screening capabilities, powered by the open-source VirtualFlow 2.0 software, to efficiently screen tens of billions of compounds for client targets. The company has demonstrated its scientific prowess through successful participation in the CACHE Challenge and contributions to published research on targets like KEAP1-NRF2 and SARS-CoV-2. As a service provider, it is likely in an early-revenue stage, catering to the growing demand for cost-effective, computational-first discovery approaches.

Leverages the open-source VirtualFlow 2.0 platform for ultra-large virtual screening (ULVS), integrated with molecular dynamics simulations, Markov State Modeling, and proprietary AI/ML methods for hit identification and lead optimization. Specializes in screening multi-billion compound libraries like Enamine REAL.

Competes with other computational chemistry/CRO service providers (e.g., Schrödinger's services arm, ChemDiv), large CROs building computational capabilities (e.g., Labcora, Charles River), and internal teams at pharmaceutical companies. Differentiation is based on direct access to and expertise with the high-performance VirtualFlow platform for ultra-large screens and a focus on challenging targets.